Medication Adherence and Monitoring
Non-adherence to a drug therapy is often the reason for not achieving the therapeutic goals in patients. Thus, measuring and monitoring drug adherence is an important aspect to understand patients’ adherence patterns and behavior as well as to provide sup
- PDF / 378,046 Bytes
- 16 Pages / 439.37 x 666.142 pts Page_size
- 79 Downloads / 258 Views
Abstract Non-adherence to a drug therapy is often the reason for not achieving the therapeutic goals in patients. Thus, measuring and monitoring drug adherence is an important aspect to understand patients’ adherence patterns and behavior as well as to provide supportive measures to enhance or reestablish adherence to a prescribed regimen. A variety of different Adherence Measurement and Monitoring Systems (AMS) exist although there is no single AMS or method considered to be the gold standard today. These range from simple Apps that issue alerts and reminders to patients up to AMS that facilitate automated, telemedical interactions between the physician and the patient to initiate corrective interventions by making use of a variety of data sources. When applied to patients with several morbidities, co-morbidities, and disabilities appropriate AMS still remain a challenge.
Keywords Mobile health (mHealth) Adherence quantification Adherence management systems Drug identification
Telehealth
This chapter builds on a previous article [1] which comprehensively elucidated the pivotal role of adherence for health care today and expands the technical aspects of the underlying concepts, in particular the relationship of Adherence Measurement and Monitoring Systems (AMS) and telehealth. It strives to give an overview on algorithm-based definitions of adherence and summarizes the current state-ofthe-art of AMS. The chapter tries to sort the huge variety of AMS into different
H. Ebner G. Schreier (&) Digital Safety and Security Department, AIT Austrian Institute of Technology GmbH, Reininghausstraße 13/1, 8020 Graz, Austria e-mail: [email protected] H. Ebner e-mail: [email protected] H. Ebner G. Schreier Institute for Neural Engineering, Graz University of Technology, Stremayrgasse 16/IV, 8010 Graz, Austria © American Association of Pharmaceutical Scientists 2016 S. Stegemann (ed.), Developing Drug Products in an Aging Society, AAPS Advances in the Pharmaceutical Sciences Series 24, DOI 10.1007/978-3-319-43099-7_31
659
660
H. Ebner and G. Schreier Topic: adherence monitoring
900 800 Publications
700 600 500 400 300 200
0
19 7 19 4 7 19 5 7 19 6 7 19 7 7 19 8 7 19 9 8 19 0 1981 8 19 2 8 19 3 8 19 4 8 19 5 1986 8 19 7 8 19 8 89 19 90 19 1991 9 19 2 9 19 3 1994 9 19 5 1996 9 19 7 9 19 8 99 20 0 20 0 2001 0 20 2 0 20 3 2004 0 20 5 0 20 6 07 20 0 20 8 0 20 9 1 20 0 2011 2012 1 20 3 2014 15
100
Relative Research Interest
0.00095 0.00090 0.00085 0.00080 0.00075 0.00070 0.00065 0.00060 0.00055 0.00050 0.00045 0.00040 0.00035 0.00030 0.00025 0.00020 0.00015 0.00010 0.00005 0.00000
1000
Publications
Publications (current year estimated)
Relative Research Interest
Relative Research Interest (smoothed)
Fig. 1 Evolution of the number of publications listed in PubMed in the topic ‘adherence monitoring’ over the years
classes based on aspects like the point of its action in the medication therapy process chain, the underlying technology or the type of communication involved and gives an outloo
Data Loading...
